Purpose: To determine the long-term dose response of novel low-dose gamma-emitting stents in a rabbit iliac artery model.
Methods And Materials: Control stents (n=24) and 103Pd stents 1.0 to 4.0 mCi (n=36) were implanted in the iliac arteries of 30 New Zealand rabbits. Stents were evaluated by intravascular ultrasound (immediately post procedure and before killing) and by histomorphometry.
Results: At 26 weeks, 28 rabbits were killed, with no evidence of stent thrombosis. In the body of the stent there was a dose-response relationship with 50% inhibition of intimal hyperplasia at the highest activity compared to control stents (p=0.07) and a significant increase in intimal hyperplasia at the lowest activity (p < 0.01). At the stent edges, there was a significant reduction of lumen area at all activity levels compared to control stents, which was most prominent at the proximal stent edge. Higher-activity stents demonstrated incomplete endothelialization and immature neointimal formation.
Conclusions: Continuous low-dose-rate irradiation by gamma-emitting 103Pd stents is feasible with reduction of in-stent hyperplasia in a dose-related manner. However, significant narrowing at the stent edges, increased in-stent hyperplasia at lower activities, and incomplete vascular healing with persistence of immature neointima at higher activities are significant limitations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0360-3016(02)02960-7 | DOI Listing |
Int J Surg Case Rep
December 2024
Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Biomedical Science, Faculty of Medicine, Universitas Surabaya, Indonesia.
Introduction And Importance: Dilation and stretching of the collecting system of the kidney due to obstruction of urine flow is called hydronephrosis. This case may be accompanied by the presence of pus known as pyonephrosis. This case report reporting massive pyonephrosis in pediatrics related to management and source of control.
View Article and Find Full Text PDFAnn Ital Chir
December 2024
Department of Cardiovascular Surgery, Shaoxing People's Hospital, 312000 Shaoxing, Zhejiang, China.
Shanghai Kou Qiang Yi Xue
October 2024
Department of Stomatology, Nanjing Gaochun People's Hospital. Nanjing 211300, China. E-mail:
Purpose: To explore the effects of personalized oral stents in intensity-modulated radiation therapy (IMRT) treatment.
Methods: Totally 108 patients with nasopharyngeal carcinoma treated with IMRT at Nanjing Gaochun People's Hospital from January 2021 to December 2023 were selected. Using a random number table method, the patients were divided into experimental group (n=54) using personalized oral stents and control group (n=54) using simple mouthpieces.
Front Med (Lausanne)
December 2024
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Objective: Retroperitoneal fibrosis (RPF) is a rare disease characterized by the presence of fibroinflammatory tissue that surrounds the abdominal aorta and the iliac arteries and often entraps the ureters. Hydronephrosis is a common complication of RPF, however, its clinical features and outcomes have not been well elucidated.
Methods: A total of 115 RPF-related hydronephrosis patients have been recruited from 9 clinical centers in China since March 2010.
Med Sci Monit
December 2024
Department of Cardiovascular, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
BACKGROUND Dual antiplatelet therapy is the main treatment for cardiovascular diseases (CADs). In this study, we evaluated the efficacy and safety of aspirin combined with low-dose rivaroxaban in the secondary prevention of high-risk ischemic cardiovascular diseases. MATERIAL AND METHODS In total, 168 patients who were diagnosed with acute myocardial infarction or multiple vessel disease 1 year after percutaneous coronary intervention were divided into 2 groups: the aspirin group (aspirin as acetylsalicylic acid: 100 mg once daily) and the aspirin + rivaroxaban group (aspirin: 100 mg once daily, rivaroxaban: 2.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!